What Medicine Should You Not Take with Wegovy: Drug Interactions, Timing Rules, and the Insulin Exception

Reviewed by FormBlends Medical Team · Last updated September 5, 2026 · Sources listed below

Key Takeaways

• Wegovy's label lists only two contraindications (a personal or family history of medullary thyroid carcinoma or MEN 2, and hypersensitivity); for other oral drugs it asks for monitoring where the therapeutic index is narrow, not timing separation (Wegovy label, June 2026)
• The label says to consider reducing insulin or sulfonylurea doses when starting Wegovy to lower hypoglycemia risk; it gives no percentage and notes that adding Wegovy to insulin has not been evaluated
• Combining Wegovy with another GLP-1 medicine (Ozempic, Rybelsus, Saxenda, Victoza, Trulicity, Mounjaro, Zepbound or compounded versions) has not been studied and is not recommended
• In label studies, injectable semaglutide did not change the absorption of oral contraceptives, warfarin, metformin, digoxin or several other oral drugs; the semaglutide tablet raised levothyroxine exposure by 33 percent, so thyroid monitoring is advised

The short answer

Wegovy (semaglutide) has two label contraindications, neither involving another medication: a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and a prior serious hypersensitivity reaction. Its drug-interaction section asks for two things: consider reducing insulin or sulfonylurea doses because of hypoglycemia risk, and monitor oral drugs with a narrow therapeutic index because Wegovy delays gastric emptying (Wegovy label, revised June 2026). Combining it with another GLP-1 medicine is not recommended. Most other interactions are about monitoring, not avoidance.

Table of contents

1. The core mechanism: why Wegovy changes how other drugs absorb
2. Other GLP-1 medications: not studied, not recommended
3. Medications requiring dose reduction, not avoidance
4. Oral medications requiring timing separation
5. What most articles get wrong about birth control and Wegovy
6. The insulin dose-reduction protocol
7. Medications that work normally without adjustment
8. The FormBlends timing framework for oral medications
9. When delayed absorption becomes a clinical problem
10. Supplements and over-the-counter medications
11. The decision tree: adjust timing, adjust dose, or avoid entirely
12. Wegovy versus Zepbound: what each label actually says about other medicines
13. Label-verified interaction studies
14. Surgery and anesthesia: what changed by 2026
15. FAQ

The core mechanism: why Wegovy changes how other drugs absorb

Wegovy's active ingredient, semaglutide, is a GLP-1 receptor agonist. The label says only that Wegovy "delays gastric emptying" (section 7.2). The one quantitative human study, in 30 adults with obesity on semaglutide 1 mg, found first-hour gastric emptying about 27 percent lower than placebo (exposure ratio 0.73) and no statistically significant difference over the full 5 hours (Hjerpsted et al., Diabetes, Obesity and Metabolism 2018). Correction, September 2026: an earlier version stated a 60 to 70 percent slowing and a half-time of 3 to 5 hours; neither figure has a source, and both have been removed.

This delay affects oral medication absorption in two ways:

1. Time to peak concentration increases. A pill that normally reaches peak blood levels in 1 to 2 hours may take 3 to 4 hours on semaglutide. For most medications, this doesn't matter clinically. For time-sensitive drugs (migraine abortives, some antibiotics, emergency contraception), it does.

1. Total absorption may decrease. Some medications have absorption windows in the upper small intestine. If the pill sits in the stomach too long, it may pass through the optimal absorption site before dissolving fully. This is rare but documented for a handful of drugs.

How the delay changes across the weekly dosing cycle has not been measured for Wegovy. The tirzepatide label notes that its gastric-emptying delay is largest after the first dose and diminishes over time (Zepbound label, section 12.2); the Wegovy label makes no such statement. Correction, September 2026: an earlier version described a day-by-day weekly rhythm that had no source.

Hjerpsted et al. (Diabetes, Obesity and Metabolism 2018) used acetaminophen absorption as a gastric-emptying proxy: first-hour acetaminophen exposure on semaglutide 1 mg was 0.73 times that on placebo, while overall exposure over 5 hours was not significantly different. In other words, oral drugs may start absorbing a little later, but the total amount absorbed was unchanged. Correction, September 2026: an earlier version cited this study as 2021 in Clinical Pharmacokinetics with a 47 percent figure; the journal, year and figure have been corrected.

Other GLP-1 medications: not studied, not recommended

Combining Wegovy with another GLP-1 receptor agonist has not been studied and is not recommended; manufacturers advise against it (Medical News Today, July 2026). It is not, however, a label contraindication. This includes:

• Ozempic (semaglutide for diabetes, same active ingredient as Wegovy)
• Rybelsus (oral semaglutide)
• Saxenda or Victoza (liraglutide)
• Trulicity (dulaglutide)
• Mounjaro or Zepbound (tirzepatide, a dual GLP-1/GIP agonist)
• Compounded semaglutide or compounded tirzepatide

Combining GLP-1 medications has no studied benefit and would be expected to add gastrointestinal side effects. The label's actual contraindications are different: a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and a prior serious hypersensitivity reaction to semaglutide (Wegovy label, section 4).

This sounds obvious, but it happens in practice when patients switch from Ozempic to Wegovy without realizing they contain the same drug, or when a patient on compounded semaglutide adds brand-name Wegovy thinking "more is better." It's not. It's redundant and unstudied.

If you're switching from one GLP-1 to another, stop the first medication entirely before starting the second. No overlap period.

Medications requiring dose reduction, not avoidance

Several medication classes require dose adjustments when starting Wegovy, but are not contraindicated. The adjustment is proactive (before hypoglycemia or other adverse effects occur), not reactive.

Insulin (all types).

Semaglutide lowers blood glucose. The Wegovy label (section 7.1, June 2026) says the risk of hypoglycemia is increased when Wegovy is used with insulin or an insulin secretagogue, that "the addition of WEGOVY in patients treated with insulin has not been evaluated," and that prescribers should "consider reducing the dose of concomitantly administered insulin secretagogue or insulin." It gives no percentages, and neither does any Wegovy trial. Correction, September 2026: an earlier version printed a step-by-step percentage protocol attributed to the SUSTAIN trials (Marso et al., 2016). That trial was a cardiovascular outcomes study containing no such protocol, and the percentages have been removed. Your prescriber sets any insulin change.

Sulfonylureas (glipizide, glyburide, glimepiride).

Sulfonylureas stimulate insulin release from the pancreas. In the label's type 2 diabetes trial (STEP 2), clinically significant hypoglycemia occurred in 6.2 percent of Wegovy participants versus 2.5 percent on placebo, and the label notes the risk is higher with insulin or a sulfonylurea (section 5.4). The label's instruction is to consider reducing the sulfonylurea dose when starting Wegovy and to monitor glucose; the amount is the prescriber's decision. Correction, September 2026: an earlier version cited SUSTAIN-2 with 41 and 11 percent hypoglycemia rates and a 50 percent dose cut. SUSTAIN-2 compared semaglutide with sitagliptin and had no sulfonylurea arm; those figures were wrong and have been removed.

Warfarin.

Warfarin has a narrow therapeutic window and is affected by changes in diet, weight, and vitamin K intake. Semaglutide causes weight loss and often changes eating patterns, both of which can alter warfarin metabolism and effect.

The adjustment:

• Monitor INR weekly for the first 4 weeks after starting semaglutide
• Expect INR to drift as weight loss accelerates (typically weeks 4 to 12)
• Adjust warfarin dose to maintain target INR
• Recheck INR stability once weight loss plateaus

No initial dose reduction is needed, but closer monitoring is. In a formal interaction study, semaglutide did not change warfarin exposure (Hausner et al., Clinical Pharmacokinetics 2017), and the label lists S- and R-warfarin among drugs with no clinically significant change (section 12.3); the label still asks for increased monitoring of narrow-therapeutic-index drugs (section 7.2). Correction, September 2026: an earlier version cited a 2022 case series (Davidson et al.) that could not be found in PubMed; it has been removed.

Oral medications requiring timing separation

The Wegovy label does not ask for timing separation of any oral drug; it asks for monitoring where a drug has a narrow therapeutic index (section 7.2). The medicines below carry their own timing rules for reasons unrelated to Wegovy, and those rules still apply. Correction, September 2026: an earlier version prescribed a 30-to-60-minute separation rule during the first 4 to 6 weeks; it had no source and has been removed.

Levothyroxine (Synthroid, Levoxyl).

Levothyroxine absorption occurs in the small intestine and is sensitive to food, calcium and iron, which is why its own labeling says to take it on an empty stomach. The direction of the semaglutide effect is the opposite of what many articles assume: in a study with the semaglutide tablet, total thyroxine exposure rose by 33 percent with peak concentration unchanged (Wegovy label, section 12.3); injectable semaglutide did not affect the absorption of oral medications (section 7.2). The label's advice is to monitor thyroid parameters.

The protocol:

• Take levothyroxine on an empty stomach, 60 minutes before breakfast
• Follow the levothyroxine label's standard instruction (30 to 60 minutes before breakfast)
• Recheck TSH 6 to 8 weeks after starting semaglutide or after dose changes
• Adjust levothyroxine dose if TSH drifts out of range

Correction, September 2026: an earlier version cited a 2023 study in Thyroid (Cappelli et al.) reporting that 18 percent of patients needed levothyroxine increases after starting GLP-1 therapy. It could not be found in PubMed, and the label reports the opposite direction (higher exposure with the tablet). It has been removed; the monitoring advice stands.

Oral bisphosphonates (alendronate, risedronate).

Bisphosphonates require an empty stomach and upright posture for 30 to 60 minutes to prevent esophageal irritation. Delayed gastric emptying on semaglutide increases esophageal contact time.

The protocol:

• Take bisphosphonate first thing in the morning with 8 oz water
• Remain upright for 60 minutes (not 30) during semaglutide treatment
• Do not eat or take other medications during the 60-minute window
• If esophageal discomfort occurs, discuss switching to IV bisphosphonate (zoledronic acid) with your provider

Antibiotics requiring rapid absorption.

Most antibiotics have no documented interaction with Wegovy. Two notes:

• Fluoroquinolones (ciprofloxacin, levofloxacin): no Wegovy timing rule exists; follow the antibiotic's own instructions. Fluoroquinolones can affect blood glucose on their own, which matters if you also take insulin or a sulfonylurea (GoodRx, May 2026)
• Azithromycin: no Wegovy-specific guidance; take as directed

For chronic suppressive antibiotics (nitrofurantoin for recurrent UTI, doxycycline for acne), timing is less critical.

What most articles get wrong about birth control and Wegovy

The most common error in GLP-1 drug interaction content is the claim that Wegovy reduces oral contraceptive effectiveness. This is incorrect and stems from misreading the prescribing information.

What the Wegovy prescribing information actually says:

"WEGOVY causes a delay of gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology trials with semaglutide 1 mg once weekly injection, semaglutide did not affect the absorption of orally administered medications" (Wegovy label, section 7.2, revised June 2026). Section 12.3 lists ethinyl estradiol and levonorgestrel among drugs with no clinically significant change in exposure.

Correction, September 2026: the block quote in an earlier version, including the sentence about switching to a non-oral contraceptive or adding a barrier method for 4 weeks after starting and after each dose increase, is from the tirzepatide label (Zepbound, section 7.2), not from Wegovy's. That instruction applies to Zepbound and Mounjaro, not to Wegovy.

What this means in practice:

The formal drug interaction study for oral contraceptives (Kapitza et al., Journal of Clinical Pharmacology 2015) found that semaglutide did not reduce the bioavailability of a combined ethinylestradiol and levonorgestrel pill. A separate study (Hausner et al., Clinical Pharmacokinetics 2017) found no interaction with metformin, warfarin, atorvastatin or digoxin. Correction, September 2026: an earlier version attributed the contraceptive result to Hausner 2020; the citation has been corrected.

The Wegovy label contains no contraceptive warning at all. If you take tirzepatide instead, the Zepbound label does ask you to switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose escalation.

The practical recommendation:

• Oral contraceptives work normally on Wegovy
• No need to switch to non-oral methods
• No need to add barrier methods
• If you miss a pill due to nausea or vomiting (common in weeks 1 to 4 of semaglutide), follow standard missed-pill protocols

There are no interaction data for emergency contraception (Plan B, ella) with semaglutide. Take it as directed and ask a pharmacist if you have concerns.

The insulin dose-reduction protocol

Because the label asks prescribers to consider reducing insulin when starting Wegovy, patients often want the numbers. There are none to give. The Wegovy label (section 7.1, June 2026) says adding Wegovy to insulin "has not been evaluated" and only that the prescriber should "consider reducing the dose" of insulin or an insulin secretagogue. What you can do:

• Record your current insulin doses and recent glucose readings before the first Wegovy dose
• Ask your prescriber for a written plan, including which reading should trigger a call
• Monitor glucose as instructed, especially in the weeks after each Wegovy dose increase
• Know hypoglycemia symptoms and treatment; the label asks prescribers to educate patients on them (section 5.4)

Correction, September 2026: an earlier version of this section printed a five-step protocol with specific percentage reductions and glucose thresholds. Those numbers were not from any label or trial and have been removed.

Medications that work normally without adjustment

The following medications have been studied in combination with semaglutide and require no dose or timing changes:

Metformin. No interaction in a formal study (Hausner et al., 2017) and no clinically significant change per the label (section 12.3). Metformin and semaglutide are commonly prescribed together.

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin). No interaction. Can be combined safely. Monitor for dehydration risk, especially during the first 4 weeks when nausea is most common.

DPP-4 inhibitors (sitagliptin, linagliptin). No safety interaction, but limited additional benefit. Both DPP-4 inhibitors and GLP-1 agonists increase incretin activity. The combination is redundant rather than synergistic. Most providers discontinue DPP-4 inhibitors when starting semaglutide.

Statins (atorvastatin, rosuvastatin, simvastatin). No interaction. Semaglutide modestly improves lipid profiles independently, but statins remain indicated for cardiovascular risk reduction.

ACE inhibitors and ARBs (lisinopril, losartan). No interaction. Commonly prescribed together in patients with diabetes and hypertension.

SSRIs and SNRIs (sertraline, escitalopram, duloxetine). No interaction. Semaglutide does not affect cytochrome P450 enzymes, so psychiatric medications metabolized by CYP2D6, CYP3A4, etc., are unaffected.

Anticoagulants other than warfarin (apixaban, rivaroxaban, dabigatran). No interaction. Unlike warfarin, these direct oral anticoagulants (DOACs) are not affected by diet or weight changes, so semaglutide-induced weight loss doesn't alter dosing.

Proton pump inhibitors (omeprazole, esomeprazole). No interaction. PPIs are commonly used to manage GLP-1-induced reflux and work normally.

Benzodiazepines (alprazolam, lorazepam). No interaction.

NSAIDs (ibuprofen, naproxen). No interaction, but use caution. Semaglutide can cause nausea and GI upset; adding NSAIDs (which also irritate the GI tract) may worsen symptoms. Not contraindicated, just use the lowest effective dose.

The FormBlends timing framework for oral medications

One practical way to organize your medicines during Wegovy titration is in three phases. None of this is a label requirement, and no Wegovy study has measured absorption week by week:

Phase 1: Acute adaptation (weeks 1 to 4).

Nausea is most common in the first weeks. Some patients report that oral medications "sit heavy" or cause more nausea if taken with food.

Timing rule: take time-sensitive oral medications (levothyroxine, bisphosphonates, antibiotics for acute infection) 60 minutes before breakfast or 3 to 4 hours after dinner. Non-time-sensitive medications can be taken as usual, but if nausea worsens, separate from meals.

Phase 2: Dose escalation (weeks 5 to 16).

Each dose increase can bring gastrointestinal symptoms back for a while; no study has timed this for Wegovy.

Timing rule: tighten timing separation on injection day through day 3. Relax on days 5 to 7. For medications taken daily, keep the 60-minute pre-meal rule during escalation.

Phase 3: Maintenance (week 16 onward).

Gastric emptying stabilizes at the new baseline. Most patients stop noticing the "slow stomach" feeling. Medication absorption normalizes for most drugs.

Timing rule: levothyroxine and bisphosphonates still benefit from 60-minute separation (this is standard practice even without semaglutide). Other medications can return to usual timing unless individual symptoms suggest otherwise.

This framework is general guidance for organizing your medicines, not a controlled-trial result, and the Wegovy label itself asks for monitoring rather than timing separation.

When delayed absorption becomes a clinical problem

For most medications, delayed absorption is a pharmacokinetic curiosity, not a clinical problem. The drug still works; it just takes longer to reach peak levels. But there are scenarios where timing matters enough to change outcomes.

Migraine abortive medications (triptans, NSAIDs, ergotamines).

Migraine treatment works best when started early in the headache phase. Delayed absorption means delayed relief, which reduces efficacy. If you treat migraines with oral triptans (sumatriptan, rizatriptan) and notice they work more slowly on semaglutide, consider:

• Switching to a triptan nasal spray or subcutaneous injection (bypasses gastric absorption)
• Taking the triptan at the first sign of aura or prodrome, not waiting for pain
• Discussing preventive migraine medications with your provider if abortive treatment becomes unreliable

Antibiotics for acute severe infection.

For mild infections (uncomplicated UTI, mild sinusitis), delayed antibiotic absorption rarely matters. For severe infections (pneumonia, pyelonephritis, sepsis risk), it does. If you're prescribed antibiotics for a serious infection while on semaglutide, ask your provider whether IV antibiotics are indicated, especially in the first 24 to 48 hours.

Seizure medications (levetiracetam, lamotrigine, phenytoin).

Seizure control depends on stable blood levels. Semaglutide-induced delayed absorption could theoretically destabilize levels, though this has not been reported in published case series. If you have epilepsy and start semaglutide, monitor for breakthrough seizures and discuss checking drug levels with your neurologist 4 to 6 weeks after starting treatment.

Chemotherapy agents (oral capecitabine, temozolomide).

Oral chemotherapy requires precise dosing and absorption. If you're on oral chemotherapy and considering semaglutide for weight management or diabetes, discuss timing with your oncologist. In most cases, semaglutide is deferred until chemotherapy is complete.

Supplements and over-the-counter medications

Multivitamins and fat-soluble vitamins (A, D, E, K).

Fat-soluble vitamins require dietary fat for absorption. Semaglutide reduces fat intake (patients naturally eat less fat due to nausea and early satiety) and slows gastric emptying. This can reduce absorption modestly.

The recommendation: take fat-soluble vitamins or multivitamins with your largest meal of the day, which is more likely to contain some fat. If you're on semaglutide long-term, check vitamin D levels annually and supplement if deficient.

Calcium and iron.

Both require an acidic stomach environment for optimal absorption. Semaglutide doesn't reduce stomach acid, but if you're also taking a PPI for reflux (common on GLP-1 medications), absorption may decrease.

The recommendation: take calcium citrate (not calcium carbonate) if you're on a PPI, as citrate doesn't require acid for absorption. Take iron with vitamin C (orange juice, a vitamin C tablet) to enhance absorption, and separate from calcium by 2+ hours.

Fiber supplements (psyllium, methylcellulose).

Fiber supplements slow gastric emptying further. Combined with semaglutide, this can worsen nausea and bloating.

The recommendation: if you need fiber for constipation (common on semaglutide), start with a low dose (half the usual amount) and increase gradually. Take fiber supplements 3 to 4 hours after your last meal, not with meals.

Probiotics.

No interaction. Probiotics are often helpful for GLP-1-induced GI symptoms (bloating, constipation, diarrhea). Take as directed on the package.

Melatonin and sleep aids.

No interaction. Melatonin, diphenhydramine (Benadryl), and doxylamine (Unisom) work normally on semaglutide.

Caffeine (coffee, energy drinks, pre-workout supplements).

No interaction, but caffeine on an empty stomach can worsen nausea, which is already common on semaglutide. If you drink coffee, have it with or after food during the first 4 to 6 weeks of treatment.

The decision tree: adjust timing, adjust dose, or avoid entirely

Use this decision tree to determine how to handle a specific medication when starting Wegovy or compounded semaglutide.

Question 1: Is the medication another GLP-1 receptor agonist?

• Yes → Stop the other GLP-1 entirely before starting semaglutide. No overlap.
• No → Proceed to question 2.

Question 2: Is the medication insulin or a sulfonylurea?

• Yes → Your prescriber should consider a dose reduction (Wegovy label, section 7.1); the amount is their call. Monitor glucose closely.
• No → Proceed to question 3.

Question 3: Is the medication warfarin?

• Yes → No dose change initially, but monitor INR weekly for 4 weeks, then as needed.
• No → Proceed to question 4.

Question 4: Does the medication require rapid absorption for efficacy (migraine abortives, emergency contraception, antibiotics for severe acute infection)?

• Yes → There is no Wegovy timing rule; if a fast-acting drug seems slower, ask about a non-oral formulation (nasal spray, injection, IV).
• No → Proceed to question 5.

Question 5: Is the medication levothyroxine or a bisphosphonate?

• Yes → Follow the drug's own instructions (empty stomach, upright). Recheck TSH for levothyroxine after starting semaglutide, as the label advises monitoring.
• No → Proceed to question 6.

Question 6: Is the medication an oral contraceptive?

• Yes → No change needed for Wegovy; label studies showed no change in ethinyl estradiol or levonorgestrel exposure. If you take tirzepatide instead, its label calls for a backup method for 4 weeks after starting and after each escalation.
• No → Proceed to question 7.

Question 7: Is the medication on the "works normally" list (metformin, statins, ACE inhibitors, SSRIs, DOACs)?

• Yes → No change needed. Take as prescribed.
• No → Proceed to question 8.

Question 8: Are you unsure whether the medication interacts?

• Yes → Ask your prescribing provider or pharmacist. There is no default separation rule.

Wegovy versus Zepbound: what each label actually says about other medicines

Much of the confusion online comes from copying tirzepatide language onto semaglutide pages. As of September 5, 2026, here is what the two labels say, side by side.

Topic	Wegovy (semaglutide), label revised June 2026	Zepbound (tirzepatide), label revised August 2026
Contraindications	Personal or family history of medullary thyroid carcinoma or MEN 2; serious hypersensitivity	Same two categories
Oral contraceptives	No warning; ethinyl estradiol and levonorgestrel exposure unchanged (12.3)	Switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose escalation (7.2, 8.3)
Other oral drugs	Injectable semaglutide did not affect absorption of oral medications; monitor narrow-therapeutic-index drugs (7.2)	Monitor drugs dependent on threshold concentrations or with a narrow therapeutic index, such as warfarin (7.2)
Insulin and sulfonylureas	Consider reducing the dose; combination with insulin not evaluated (7.1)	Consider reducing the dose (7.1)
Gastric emptying	"Delays gastric emptying" (7.2)	Delay is largest after the first dose and diminishes over time (12.2)
Levothyroxine	Semaglutide tablet raised total thyroxine exposure 33 percent; monitor (12.3)	Not specifically addressed

Label-verified interaction studies

The Wegovy label (section 12.3, June 2026) reports formal pharmacokinetic studies of semaglutide with the following oral drugs. "No clinically significant change" is the label's own conclusion.

Drug studied	Result	Independent publication
Metformin	No clinically significant change	Hausner et al., 2017
Warfarin (S- and R-)	No clinically significant change; monitoring still advised	Hausner et al., 2017
Digoxin	No clinically significant change	Hausner et al., 2017
Atorvastatin	No clinically significant change	Hausner et al., 2017
Ethinyl estradiol and levonorgestrel	No clinically significant change	Kapitza et al., 2015
Lisinopril, furosemide, rosuvastatin	No clinically significant change	Label section 12.3
Levothyroxine (with semaglutide tablet)	Total thyroxine exposure increased 33 percent; peak unchanged	Label section 12.3

The label also states that semaglutide has very low potential to affect cytochrome P450 enzymes, which is why antidepressants and most other liver-metabolized drugs are not expected to interact.

Surgery and anesthesia: what changed by 2026

In 2023 the American Society of Anesthesiologists suggested holding weekly GLP-1 drugs for a week before elective procedures. Two things have since changed. The Wegovy label (section 5.10, June 2026) now describes rare postmarketing reports of pulmonary aspiration during general anesthesia or deep sedation in patients with residual gastric contents despite fasting, and states that available data are insufficient to say whether stopping the drug or changing fasting instructions reduces that risk; its instruction is to tell your healthcare providers about any planned procedure. And in 2024 a multisociety clinical practice guidance from the AGA, ASA, ASMBS, ISPCOP and SAGES moved from a blanket hold to individualized, shared decision-making based on the patient's symptoms and the procedure. The practical step is the same either way: tell the surgical and anesthesia team you take Wegovy well before the date, and follow their instructions on fasting and dosing.

FAQ

Can I take Tylenol or ibuprofen with Wegovy?

Yes. Acetaminophen (Tylenol) and ibuprofen (Advil, Motrin) have no interaction with semaglutide. Absorption may be slightly delayed, but efficacy is unchanged. Take with food if possible to reduce GI irritation, especially for ibuprofen.

Do I need to stop my blood pressure medication on Wegovy?

No. Blood pressure medications (ACE inhibitors, ARBs, beta blockers, calcium channel blockers, diuretics) work normally on semaglutide. As you lose weight, your blood pressure may improve, and your provider may reduce doses, but this is a positive outcome, not an interaction.

Can I take antidepressants with Wegovy?

Yes. SSRIs, SNRIs, tricyclic antidepressants, and bupropion have no interaction with semaglutide. Semaglutide does not affect the cytochrome P450 enzyme system, so psychiatric medications are unaffected.

Does Wegovy interact with alcohol?

Semaglutide does not interact with alcohol pharmacologically, but alcohol can worsen nausea and increase hypoglycemia risk if you're also on insulin or sulfonylureas. No formal interaction study exists; some people report feeling alcohol's effects sooner, but that has not been measured.

Can I take omeprazole or other antacids with Wegovy?

Yes. Proton pump inhibitors (omeprazole, esomeprazole, pantoprazole), H2 blockers (famotidine, ranitidine), and antacids (Tums, Maalox) are commonly used to manage GLP-1-induced reflux and have no interaction with semaglutide.

Should I take my thyroid medication at a different time on Wegovy?

Keep taking levothyroxine as its own label directs, on an empty stomach 30 to 60 minutes before breakfast. The Wegovy label reports that the semaglutide tablet raised total thyroxine exposure by 33 percent and asks for thyroid monitoring, so have TSH rechecked after starting Wegovy or changing doses and let your prescriber adjust.

Can I take Wegovy if I'm on chemotherapy?

This depends on the type of chemotherapy and your oncologist's assessment. Oral chemotherapy agents may have altered absorption on semaglutide. IV chemotherapy is unaffected. Discuss with your oncology team before starting semaglutide.

Does Wegovy affect birth control pills?

No. A formal interaction study (Kapitza et al., 2015) and the Wegovy label (section 12.3) show no clinically significant change in ethinyl estradiol or levonorgestrel exposure. Follow missed-pill rules if vomiting makes you miss a dose. The 4-week backup-method advice applies to tirzepatide (Zepbound, Mounjaro), not Wegovy.

Can I take antibiotics while on Wegovy?

Yes. There is no Wegovy-specific antibiotic interaction in the label. Take antibiotics as their own instructions direct; for a severe infection, your clinician decides on oral versus IV treatment on clinical grounds, not because of Wegovy.

Do I need to stop Wegovy before surgery?

Tell your surgeon and anesthesia team you take Wegovy. The label (section 5.10, June 2026) reports rare cases of pulmonary aspiration under general anesthesia or deep sedation and says available data are insufficient to recommend whether to stop the drug or change fasting. A 2024 multisociety guidance (AGA, ASA, ASMBS, ISPCOP, SAGES) recommends individualized shared decision-making rather than a blanket 1-week hold.

Can I take vitamin D and calcium with Wegovy?

Yes. Take vitamin D with a meal containing some fat for better absorption. If you're on a PPI for reflux, use calcium citrate instead of calcium carbonate, and separate calcium from iron supplements by 2+ hours.

Does Wegovy interact with metformin?

No. Metformin and semaglutide are commonly prescribed together with no interaction. This combination is standard therapy in many diabetes treatment protocols.

Is taking Wegovy with Zepbound or Mounjaro a contraindication?

It is not listed as a contraindication in either label, but the combination has never been studied and manufacturers advise against it (Medical News Today, July 2026). Wegovy's only label contraindications are a personal or family history of medullary thyroid carcinoma or MEN 2 and a prior serious hypersensitivity reaction (section 4, June 2026). If you are switching from one GLP-1 medicine to another, stop the first before starting the second.

What are Wegovy's actual contraindications?

Two, per section 4 of the June 2026 label: a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and a prior serious hypersensitivity reaction to semaglutide or any Wegovy ingredient. No other medication is a contraindication. Pregnancy is not a contraindication either, but the label says to stop Wegovy when pregnancy is recognized and at least 2 months before a planned pregnancy.

Does Wegovy change how much of my blood pressure pill is absorbed?

For lisinopril, the label's pharmacokinetic study found no clinically significant change in exposure with semaglutide (Wegovy label, section 12.3, June 2026), and injectable semaglutide did not affect absorption of oral medications in its clinical pharmacology trials. Blood pressure often falls with weight loss, so your prescriber may lower doses over time, but that is an effect of losing weight rather than a drug interaction.

Related guides

• What Not to Take with Zepbound: Drug Interactions, Timing Rules, and the Medications That Actually Matter
• When to Take Wegovy: Why It's Not a Pill, and the Exact Weekly Injection Timing Protocol That Maximizes Efficacy
• What Vitamins Should Not Be Taken with Mounjaro: The Absorption Problem and Timing Protocol
• Can I Take Tirzepatide at Night? The Complete Timing Protocol Based on Pharmacokinetics, Not Convenience Marketing
• Tirzepatide and Antidepressants: Safe to Combine? Drug Interactions (2026)
• How to Get $25 Wegovy: The Savings Card, Eligibility Rules, and What to Do If You Do Not Qualify

Sources

1. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018.
2. Ahrén B et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2). Lancet Diabetes Endocrinol. 2017.
3. Hausner H et al. Effect of semaglutide on the pharmacokinetics of metformin, warfarin, atorvastatin and digoxin in healthy subjects. Clin Pharmacokinet. 2017.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021.
5. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
6. Smits MM et al. Effect of GLP-1 receptor agonists on gastric emptying in type 2 diabetes. Diabetes Care. 2016.
7. Nauck MA et al. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care. 2009.
8. American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes 2024. Diabetes Care. 2024.
9. Novo Nordisk. Wegovy (semaglutide) prescribing information, revised June 2026, via DailyMed.
10. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8). Diabetes Care. 2019.
11. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7). Lancet Diabetes Endocrinol. 2018.
12. DailyMed (NIH). Wegovy (semaglutide) prescribing information: sections 4, 5.4, 5.10, 7.1, 7.2, 8.1, 8.3 and 12.3. Revised June 2026, published June 30, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
13. DailyMed (NIH). Zepbound (tirzepatide) prescribing information: sections 7.2, 8.3 and 12.2 (oral contraceptive and gastric emptying language). Published September 2, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
14. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism, 2018. PMID 28941314. https://europepmc.org/article/MED/28941314
15. Hausner H et al. Effect of semaglutide on the pharmacokinetics of metformin, warfarin, atorvastatin and digoxin in healthy subjects. Clinical Pharmacokinetics, 2017. PMID 28349387. https://europepmc.org/article/MED/28349387
16. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive ethinylestradiol/levonorgestrel. Journal of Clinical Pharmacology, 2015. PMID 25475122. https://europepmc.org/article/MED/25475122
17. Ahrén B et al. SUSTAIN 2: once-weekly semaglutide versus once-daily sitagliptin. Lancet Diabetes and Endocrinology, 2017. PMID 28385659. https://europepmc.org/article/MED/28385659
18. Multisociety clinical practice guidance (AGA, ASMBS, ASA, ISPCOP, SAGES). Perioperative management of patients on GLP-1 receptor agonists. 2024. PMID 39480373. https://europepmc.org/article/MED/39480373
19. GoodRx. Wegovy interactions (hypoglycemia risk with insulin, sulfonylureas and some antibiotics). Updated May 5, 2026. https://www.goodrx.com/wegovy/interactions
20. Medical News Today. Wegovy interactions: other GLP-1 drugs, alcohol, anesthesia. Updated July 17, 2026. https://www.medicalnewstoday.com/articles/drugs-wegovy-interactions

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Saxenda, Victoza, and Trulicity are registered trademarks of their respective owners. Synthroid, Levoxyl, Plan B, Tylenol, Advil, Motrin, Prilosec, Nexium, Protonix, Pepcid, Tums, and Maalox are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.